2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
1214
Neoplasms
1024
Carcinoma, Non-Small-Cell Lung
851
Prostatic Neoplasms
683
Colorectal Neoplasms
608
Lung Neoplasms
575
Neoplasm Metastasis
431
Multiple Myeloma
420
Leukemia, Myeloid, Acute
394
Pancreatic Neoplasms
371
Ovarian Neoplasms
359
Melanoma
317
Carcinoma, Hepatocellular
284
Recurrence
274
Squamous Cell Carcinoma of Head and Neck
272
Brain Neoplasms
264
Glioblastoma
245
Head and Neck Neoplasms
241
Stomach Neoplasms
236
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Carcinoma, Renal Cell
225
Lymphoma
221
Triple Negative Breast Neoplasms
216
Endometrial Neoplasms
207
Hematologic Neoplasms
206
Urinary Bladder Neoplasms
195
Lymphoma, Non-Hodgkin
194
Sarcoma
189
Uterine Cervical Neoplasms
187
Glioma
187
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
90 days
×
Clear all
NCT03933826
2026-05-12
CISTO
University of Washington
Active not recruiting
570 enrolled
27 charts
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled